Respiratory fluoroquinolones are antibacterial agents with high tropism for respiratory tract pathogens. They feature prolonged duration of action, excellent bioavailability, and high activity against atypical and Gram-positive microorganisms.
Main IndicationRespiratory tract infections and community-acquired pneumonia
Duration of ActionProlonged effect up to 24 hours
Atypical FloraHigh efficacy against chlamydia, legionella, and mycoplasma
Age RestrictionContraindicated under 18 years of age due to chondrotoxicity
Antimicrobial Spectrum and Features
This class demonstrates expanded capabilities compared to earlier generations:
Gram-positive flora: Enhanced efficacy against pneumococci, streptococci, staphylococci, including methicillin-resistant strains (MRSA).
Gram-negative flora: High level of activity is fully preserved.
Atypical flora: Intracellular pathogens are inhibited as effectively as by macrolides and tetracyclines (Chlamydia spp., Legionella spp., Mycoplasma spp.).
Anaerobes: Taking moxifloxacin as an example, activity against Clostridium spp. and Bacteroides spp. is noted, allowing monotherapy for mixed infections.
Pharmacokinetics and Routes of Administration
The drugs have pronounced pharmacokinetic advantages:
Bioavailability: Exceeds the indicators of first-generation agents.
Convenience of administration: Prolonged action up to 24 hours improves patient compliance.
Routes of administration: Both oral (per os) and parenteral (intravenous) administration are permitted.
Clinical Indications
The term "respiratory" became associated with this group due to their ability to effectively eradicate respiratory pathogens. Main application areas:
Upper and lower respiratory tract infections (bronchitis, sinusitis, otitis media, pneumonia, including community-acquired).
Specific protocols: combination therapy for tuberculosis.
Side Effects and Safety
Adverse reactions affect multiple organ systems:
Gastrointestinal tract: Dyspeptic symptoms.
Nervous system: Insomnia, development of peripheral neuropathies, seizures.
Allergy and skin: Hypersensitivity reactions, as well as photosensitization under sunlight.
Musculoskeletal system: Arthropathies, myalgias, arthralgias, and tendon inflammation (tendinitis) associated with impaired cartilage development.
Risk factors for tendon rupture: Concurrent physical exertion and glucocorticoid use.
Contraindications: Age under 18 years, pregnancy, and lactation due to the risk of cartilage damage (exception — administration to children for life-threatening indications).
Mnemonic
"Respiratory cartilage at risk in children": respiratory agents are for breathing, but under 18 and in pregnant women they are contraindicated due to chondrotoxicity.
Frequently asked questions
Which drugs belong to the group of respiratory fluoroquinolones?
The respiratory fluoroquinolones (third and fourth generations) include levofloxacin, moxifloxacin, and gemifloxacin.
Levofloxacin (levofloxacin) — a third-generation agent, administered at 0.5 g once daily.
Moxifloxacin (moxifloxacin) — a fourth-generation agent, administered at 0.4 g once daily.
Gemifloxacin (gemifloxacin) — included among the respiratory fluoroquinolones.
How do respiratory fluoroquinolones interact with antacids and iron supplements?
When taken simultaneously with antacids and iron supplements, respiratory fluoroquinolones form non-absorbable complexes, which prevents absorption and reduces bioavailability.
Antacids contain magnesium, calcium, or aluminum ions; iron supplements also interact with fluoroquinolones.
Correction method — fluoroquinolones must be administered strictly 4 hours after taking these medications.
Why are these fluoroquinolones called "respiratory"?
This designation stuck because of the high drug tropism toward respiratory tract pathogens and their ability to effectively manage community-acquired pneumonia and bronchitis.
What are the main restrictions on prescribing this group of drugs?
The drugs are contraindicated in children under 18, pregnant women, and nursing mothers due to the risk of cartilage tissue damage (chondrotoxicity).
What factors increase the risk of tendon rupture during fluoroquinolone therapy?
The risk increases significantly with physical exertion during therapy combined with concurrent glucocorticoid use.
Go deeper
Comparison of Gram-positive activity between early and late generation fluoroquinolones
Clinical significance of the anaerobic activity of moxifloxacin in mixed infections
Mechanisms of chondrotoxicity and tendon injury development
Pharmacokinetic features: bioavailability and daily concentration profile
Safety rules regarding photosensitization and neurological adverse effects